Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland

Anna Margrét Halldórsdóttir, Margrét Sigurdardóttir, Jón Gunnlaugur Jónasson, Margrét Oddsdóttir, Jónas Magnússon, Jeffrey R. Lee, James R. Goldenring

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Recent studies have described a spasmolytic polypeptide-expressing metaplastic cell lineage (SPEM) in the gastric fundic mucosa associated with both chronic H. pylori infection and gastric adenocarcinoma. We investigated the association of SPEM both with early gastric adenocarcinoma and in biopsies taken from patients prior to diagnosis of cancer. Two cohorts were examined. First, gastric resections from 29 patients with early gastric cancer were examined. Second, biopsies taken from 18 patients prior to the diagnosis of gastric cancer were compared with their respective resection specimens as well as with control biopsies from a cohort of 19 patients diagnosed with gastritis without subsequent development of cancer. The presence of SPEM and intestinal metaplasia (IM) adjacent to and distant from the cancer was compared and spasmolytic polypeptide (SP) immunostaining within dysplastic/cancerous cells was identified. SPEM was present adjacent to cancer in all early cancer cases where the tumor was located in the body or at the body/antrum junction, and was present in the body mucosa distant from the cancer in 76% of cases. Intestinal metaplasia was found adjacent to the tumor in 76% of cases and in body sections in 52% of resections. SP immunostaining was noted within cancer cells in 62% of tumors, and within dysplastic cells in 76% of resections where dysplasia was present. SPEM was present in 82% of the biopsies obtained prior to the diagnosis of cancer, compared with only 37% in the gastritis cohort. IM was present in only 57% of biopsies. In conclusion, SPEM is strongly associated with early gastric cancers and is observed in gastric biopsies prior to the development of cancer. In addition, early gastric cancers demonstrated a high incidence of SP expression. These results suggest that SPEM merits consideration as an important pre-neoplastic gastric lesion.

Original languageEnglish (US)
Pages (from-to)431-441
Number of pages11
JournalDigestive Diseases and Sciences
Volume48
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Iceland
Metaplasia
Stomach Neoplasms
Neoplasms
Stomach
Biopsy
Gastritis
spasmolytic polypeptide
Adenocarcinoma
Pylorus
Cell Lineage
Gastric Mucosa
Mucous Membrane

Keywords

  • Antralization
  • Dysplasia
  • Gastric adenocarcinoma
  • Metaplasia
  • Pseudopyloric metaplasia
  • Spasmolytic peptide expression
  • Trefoil proteins

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Halldórsdóttir, A. M., Sigurdardóttir, M., Jónasson, J. G., Oddsdóttir, M., Magnússon, J., Lee, J. R., & Goldenring, J. R. (2003). Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Digestive Diseases and Sciences, 48(3), 431-441. https://doi.org/10.1023/A:1022564027468

Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. / Halldórsdóttir, Anna Margrét; Sigurdardóttir, Margrét; Jónasson, Jón Gunnlaugur; Oddsdóttir, Margrét; Magnússon, Jónas; Lee, Jeffrey R.; Goldenring, James R.

In: Digestive Diseases and Sciences, Vol. 48, No. 3, 01.03.2003, p. 431-441.

Research output: Contribution to journalArticle

Halldórsdóttir, AM, Sigurdardóttir, M, Jónasson, JG, Oddsdóttir, M, Magnússon, J, Lee, JR & Goldenring, JR 2003, 'Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland', Digestive Diseases and Sciences, vol. 48, no. 3, pp. 431-441. https://doi.org/10.1023/A:1022564027468
Halldórsdóttir AM, Sigurdardóttir M, Jónasson JG, Oddsdóttir M, Magnússon J, Lee JR et al. Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Digestive Diseases and Sciences. 2003 Mar 1;48(3):431-441. https://doi.org/10.1023/A:1022564027468
Halldórsdóttir, Anna Margrét ; Sigurdardóttir, Margrét ; Jónasson, Jón Gunnlaugur ; Oddsdóttir, Margrét ; Magnússon, Jónas ; Lee, Jeffrey R. ; Goldenring, James R. / Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. In: Digestive Diseases and Sciences. 2003 ; Vol. 48, No. 3. pp. 431-441.
@article{23e8616a9a2b4d528c03f968ebcaa136,
title = "Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland",
abstract = "Recent studies have described a spasmolytic polypeptide-expressing metaplastic cell lineage (SPEM) in the gastric fundic mucosa associated with both chronic H. pylori infection and gastric adenocarcinoma. We investigated the association of SPEM both with early gastric adenocarcinoma and in biopsies taken from patients prior to diagnosis of cancer. Two cohorts were examined. First, gastric resections from 29 patients with early gastric cancer were examined. Second, biopsies taken from 18 patients prior to the diagnosis of gastric cancer were compared with their respective resection specimens as well as with control biopsies from a cohort of 19 patients diagnosed with gastritis without subsequent development of cancer. The presence of SPEM and intestinal metaplasia (IM) adjacent to and distant from the cancer was compared and spasmolytic polypeptide (SP) immunostaining within dysplastic/cancerous cells was identified. SPEM was present adjacent to cancer in all early cancer cases where the tumor was located in the body or at the body/antrum junction, and was present in the body mucosa distant from the cancer in 76{\%} of cases. Intestinal metaplasia was found adjacent to the tumor in 76{\%} of cases and in body sections in 52{\%} of resections. SP immunostaining was noted within cancer cells in 62{\%} of tumors, and within dysplastic cells in 76{\%} of resections where dysplasia was present. SPEM was present in 82{\%} of the biopsies obtained prior to the diagnosis of cancer, compared with only 37{\%} in the gastritis cohort. IM was present in only 57{\%} of biopsies. In conclusion, SPEM is strongly associated with early gastric cancers and is observed in gastric biopsies prior to the development of cancer. In addition, early gastric cancers demonstrated a high incidence of SP expression. These results suggest that SPEM merits consideration as an important pre-neoplastic gastric lesion.",
keywords = "Antralization, Dysplasia, Gastric adenocarcinoma, Metaplasia, Pseudopyloric metaplasia, Spasmolytic peptide expression, Trefoil proteins",
author = "Halld{\'o}rsd{\'o}ttir, {Anna Margr{\'e}t} and Margr{\'e}t Sigurdard{\'o}ttir and J{\'o}nasson, {J{\'o}n Gunnlaugur} and Margr{\'e}t Oddsd{\'o}ttir and J{\'o}nas Magn{\'u}sson and Lee, {Jeffrey R.} and Goldenring, {James R.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1023/A:1022564027468",
language = "English (US)",
volume = "48",
pages = "431--441",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland

AU - Halldórsdóttir, Anna Margrét

AU - Sigurdardóttir, Margrét

AU - Jónasson, Jón Gunnlaugur

AU - Oddsdóttir, Margrét

AU - Magnússon, Jónas

AU - Lee, Jeffrey R.

AU - Goldenring, James R.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Recent studies have described a spasmolytic polypeptide-expressing metaplastic cell lineage (SPEM) in the gastric fundic mucosa associated with both chronic H. pylori infection and gastric adenocarcinoma. We investigated the association of SPEM both with early gastric adenocarcinoma and in biopsies taken from patients prior to diagnosis of cancer. Two cohorts were examined. First, gastric resections from 29 patients with early gastric cancer were examined. Second, biopsies taken from 18 patients prior to the diagnosis of gastric cancer were compared with their respective resection specimens as well as with control biopsies from a cohort of 19 patients diagnosed with gastritis without subsequent development of cancer. The presence of SPEM and intestinal metaplasia (IM) adjacent to and distant from the cancer was compared and spasmolytic polypeptide (SP) immunostaining within dysplastic/cancerous cells was identified. SPEM was present adjacent to cancer in all early cancer cases where the tumor was located in the body or at the body/antrum junction, and was present in the body mucosa distant from the cancer in 76% of cases. Intestinal metaplasia was found adjacent to the tumor in 76% of cases and in body sections in 52% of resections. SP immunostaining was noted within cancer cells in 62% of tumors, and within dysplastic cells in 76% of resections where dysplasia was present. SPEM was present in 82% of the biopsies obtained prior to the diagnosis of cancer, compared with only 37% in the gastritis cohort. IM was present in only 57% of biopsies. In conclusion, SPEM is strongly associated with early gastric cancers and is observed in gastric biopsies prior to the development of cancer. In addition, early gastric cancers demonstrated a high incidence of SP expression. These results suggest that SPEM merits consideration as an important pre-neoplastic gastric lesion.

AB - Recent studies have described a spasmolytic polypeptide-expressing metaplastic cell lineage (SPEM) in the gastric fundic mucosa associated with both chronic H. pylori infection and gastric adenocarcinoma. We investigated the association of SPEM both with early gastric adenocarcinoma and in biopsies taken from patients prior to diagnosis of cancer. Two cohorts were examined. First, gastric resections from 29 patients with early gastric cancer were examined. Second, biopsies taken from 18 patients prior to the diagnosis of gastric cancer were compared with their respective resection specimens as well as with control biopsies from a cohort of 19 patients diagnosed with gastritis without subsequent development of cancer. The presence of SPEM and intestinal metaplasia (IM) adjacent to and distant from the cancer was compared and spasmolytic polypeptide (SP) immunostaining within dysplastic/cancerous cells was identified. SPEM was present adjacent to cancer in all early cancer cases where the tumor was located in the body or at the body/antrum junction, and was present in the body mucosa distant from the cancer in 76% of cases. Intestinal metaplasia was found adjacent to the tumor in 76% of cases and in body sections in 52% of resections. SP immunostaining was noted within cancer cells in 62% of tumors, and within dysplastic cells in 76% of resections where dysplasia was present. SPEM was present in 82% of the biopsies obtained prior to the diagnosis of cancer, compared with only 37% in the gastritis cohort. IM was present in only 57% of biopsies. In conclusion, SPEM is strongly associated with early gastric cancers and is observed in gastric biopsies prior to the development of cancer. In addition, early gastric cancers demonstrated a high incidence of SP expression. These results suggest that SPEM merits consideration as an important pre-neoplastic gastric lesion.

KW - Antralization

KW - Dysplasia

KW - Gastric adenocarcinoma

KW - Metaplasia

KW - Pseudopyloric metaplasia

KW - Spasmolytic peptide expression

KW - Trefoil proteins

UR - http://www.scopus.com/inward/record.url?scp=0037341652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037341652&partnerID=8YFLogxK

U2 - 10.1023/A:1022564027468

DO - 10.1023/A:1022564027468

M3 - Article

VL - 48

SP - 431

EP - 441

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 3

ER -